Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI343 plus chemotherapy in advanced pancreatic cancer
NCT06770439Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2025
- Primary completion
- Jan 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of arcotatug tavatecan in pancreatic ductal adenocarcinoma (PDAC), sponsored by Zhejiang University. Started Apr 2025; status: recruiting.
02
Drugs
arcotatug tavatecan
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06770439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770439.